Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aquestive Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AQST
Nasdaq
2834
https://aquestive.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aquestive Therapeutics Inc
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
- May 2nd, 2024 2:01 pm
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
- Apr 30th, 2024 2:01 pm
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
- Apr 29th, 2024 11:00 am
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
- Apr 25th, 2024 12:00 pm
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
- Apr 17th, 2024 12:00 pm
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
- Apr 12th, 2024 8:01 pm
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
- Apr 2nd, 2024 10:15 pm
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
- Apr 1st, 2024 12:00 pm
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
- Mar 25th, 2024 12:00 pm
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
- Mar 22nd, 2024 10:00 pm
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
- Mar 20th, 2024 1:49 am
Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ...
- Mar 19th, 2024 9:00 pm
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
- Mar 19th, 2024 8:01 pm
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
- Mar 18th, 2024 3:47 pm
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
- Mar 18th, 2024 10:46 am
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
- Mar 14th, 2024 9:23 pm
Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ...
- Mar 12th, 2024 9:00 pm
Aquestive Therapeutics Inc Reports Full Year 2023 Financial Results
- Mar 7th, 2024 6:43 pm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 4:56 pm
Aquestive Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Mar 7th, 2024 10:12 am
Scroll